Long-term diabetic complications may be ameliorated by targeting Rho kinase

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 4, 2011, Pages 318-330

  Zhou, Hong ^a   Li, Yongjun ^a  

^a Second Hospital of Hebei Medical University   (China)

Author keywords

Complications; Diabetes; Inhibitors; Rho kinase; Statins

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN II; FASUDIL; FLUINDOSTATIN; HYDROXYFASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LOSARTAN; MESSENGER RNA; NITRIC OXIDE; RHO KINASE; RHO KINASE 1; RHO KINASE 2; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; BLADDER DISEASE; CELL INFILTRATION; CELL MIGRATION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; ENZYME STRUCTURE; ENZYME SUBSTRATE; ERECTILE DYSFUNCTION; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS; HUMAN; KIDNEY FIBROSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE; VITREORETINOPATHY;

ANIMALS; DIABETES COMPLICATIONS; ENZYME ACTIVATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79955707557     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1182     Document Type: Review

References (137)

1. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003; 4(6): 446-456.
2. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97(12): 1232-1235.
3. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001; 38(6): 1307-1310.
4. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005; 238(1-2): 31-39.
5. Kishi T, Hirooka Y, Masumoto A, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005; 111(21): 2741-2747.
6. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 2002; 105(13): 1545-1547.
7. Chitaley K, Wingard CJ, Clinton Webb R, et al. Antagonism of Rho kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7(1): 119-122.
8. Nishikimi T, Akimoto K, Wang X, et al. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22(9): 1787-1796.
9. Mallat Z, Gojova A, Sauzeau V, et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 2003; 93(9): 884-888.
10. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001; 38(1): 100-104.
11. Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol 2001; 21(5): 868-873.
12. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110(3): 285-288.
13. Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J 2004; 18(7): 805-815.
14. Zeng L, Xu H, Chew TL, et al. HMG-CoA reductase inhibitor modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J 2005; 19(13): 1845-1847.
15. Xu H, Zeng L, Peng H, et al. HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signalling to extracellular matrix by preventing RhoA activation. Am J Physiol Renal Physiol 2006; 291(5): F995-F1004.
16. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50(1): 17-24.
17. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000; 103(2): 227-238.
18. Leung T, Manser E, Tan L, Lim L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 1995; 270(49): 29051-29054.
19. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996; 15(9): 2208-2216.
20. Amano M, Chihara K, Nakamura N, Kaneko T, Matsuura Y, Kaibuchi K. The COOH terminus of Rho kinase negatively regulates rho-kinase activity. J Biol Chem 1999; 274(45): 32418-32424.
21. Hart MJ, Jiang X, Kozasa T, et al. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13. Science 1998; 280(5372): 2112-2114.
22. Kozasa T, Jiang X, Hart MJ, et al. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 1998; 280(5372): 2109-2111.
23. Feng J, Ito M, Ichikawa K, et al. Inhibitory phosphorylation site for Rho associated kinase on smooth muscle myosin phosphatase. J Biol Chem 1999; 274(52): 37385-37390.
24. Sebbagh M, Renvoizé C, Hamelin J, Riché N, Bertoglio J, Bréard J. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 2001; 3(4): 346-352.
25. Sapet C, Simoncini S, Loriod B, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood 2006; 108(6): 1868-1876.
26. Chen XQ, Tan I, Ng CH, Hall C, Lim L, Leung T. Characterization of RhoA-binding kinase ROKalpha implication of the pleckstrin homology domain in ROKalpha function using region-specific antibodies. J Biol Chem 2002; 277(15): 12680-12688.
27. Turner MS, Fen-Fen-Lin, Trauger JW, Stephens J, LoGrasso P. Characterization and purification of truncated human Rho-kinase II expressed in Sf-21 cells. Arch Biochem Biophys 2002; 405(1): 13-20.
28. Ward Y, Yap SF, Ravichandran V, et al. The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J Cell Biol 2002; 157(2): 291-302.
29. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996; 15(8): 1885-1893.
30. Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996; 16(10): 5313-5327.
31. Di Cunto F, Imarisio S, Hirsch E, et al. Defective neurogenesis in citron kinase knockout mice by altered cytokinesis and massive apoptosis. Neuron 2000; 28(1): 115-127.
32. Wei L, Roberts W, Wang L, et al. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 2001; 128(15): 2953-2962.
33. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 2001; 3(4): 339-345.
34. Sebbagh M, Hamelin J, Berloglio J, Solary E, Bréard J. Direct cleavage of ROCKII by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J Exp Med 2005; 201(3): 465-471.
35. Shimada H, Rajagopalan LE. Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-κB p65. J Biol Chem 2010; 285(17): 12536-12542.
36. Kaneko T, Amano M, Maeda A, et al. Identification of calponin as a novel substrate of Rho-kinase. Biochem Biophys Res Commun 2000; 273(1): 110-116.
37. Sin WC, Chen XQ, Leung T, Lim L. RhoA binding kinase alpha translocation is facilitated by the collapse of the vimentin intermediate filament network. Mol Cell Biol 1998; 18(11): 6325-6339.
38. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999; 147(5): 1023-1038.
39. Matsui T, Maeda M, Doi Y, et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 1998; 140(3): 647-657.
40. Sumi T, Matsumoto K, Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 2001; 276(1): 670-676.
41. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 2000; 275(5): 3577-3582.
42. Maekawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999; 285(5429): 895-898.
43. Arimura N, Inagaki N, Chihara K, et al. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase: evidence for two separate signaling pathways for growth cone collapse. J Biol Chem 2000; 275(31): 23973-23980.
44. Fukata Y, Oshiro N, Kinoshita N, et al. Phosphorylation of adducin by Rho-kinase plays a crucial role in cell motility. J Cell Biol 1999; 145(2): 347-361.
45. Xie Z, Su W, Guo Z, Pang H, Post SR, Gong MC. Up-regulation of CPI-17 phosphorylation in diabetic vasculature and high glucose cultured vascular smooth muscle cells. Cardiovasc Res 2006; 69(2): 491-501.
46. Anwar KN, Fazal F, Malik AB, Rahman A. RhoA/Rho-associated kinase pathway selectively regulates thrombin-induced intercellular adhesion molecule-1 expression in endothelial cells via activation of IκB kinaseβ and phosphorylation of RelA/p65. J Immunol 2004; 173(11): 6965-6972.
47. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 2004; 14(1): 29-41.
48. Liu HW, Halayko AJ, Fernandes DJ, et al. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol 2003; 29(1): 39-47.
49. Ohtsu H, Mifune M, Frank GD, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25(9): 1831-1836.
50. Zhang J, Li XX, Bian HJ, Liu XB, Ji XP, Zhang Y. Inhibition of the activity of Rho-kinase reduces cardiomyocyte apoptosis in heart ischemia/reperfusion via suppressing JNK-mediated AIF translocation. Clin Chim Acta 2009; 401(1-2): 76-80.
51. Chen XY, Dun JN, Miao QF, Zhang YJ. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009; 83(2): 67-79.
52. Kuno M, Takai S, Matsushima-Nishiwaki R, et al. Rho-kinase inhibitors decrease TGF-beta-stimulated VEGF synthesis through stress-activated protein kinase/c-Jun N-terminal kinase in osteoblasts. Biochem Pharmacol 2009; 77(2): 196-203.
53. Ongusaha PP, Qi HH, Raj L, et al. Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 2008; 1(47): ra14.
54. Amano M, Kaneko T, Maeda A, et al. Identification of Tau and MAP2 as novel substrates of Rho-kinase and myosin phosphatase. J Neurochem 2003; 87(3): 780-790.
55. Kosako H, Amano, M, Yanagida M, et al. Phosphorylation of glial fibrillary acidic protein at the same sites by cleavage furrow kinase and Rho-associated kinase. J Biol Chem 1997; 272(16): 10333-10336.
56. Goto H, Kosako H, Tanabe K, et al. Phosphorylation of vimentin by rho-associated kinase at a unique amino-terminal site that is specifically phosphorylated during cytokinesis. J Biol Chem 1998; 273(19): 11728-11736.
57. Yasui Y, Amano M, Nagata K, et al. Roles of Rho-associated kinase in cytokinesis: mutations in Rho-associated kinase phosphorylation sites impair cytokinetic segregation of glial filaments. J Cell Biol 1998; 143(5): 1249-1258.
58. Rikitake Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 2005; 36(10): 2251-2257.
59. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96(5A): 24F-33F.
60. Homma N, Nagaoka T, Morio Y, et al. Endothelin-1 and serotonin are involved in activation of RhoA/Rho kinase signaling in the chronically hypoxic hypertensive rat pulmonary circulation. J Cardiovasc Pharmacol 2007; 50(6): 697-702.
61. Nishikawa Y, Doi M, Koji T, et al. The role of rho and rho-dependent kinase in serotonin-induced contraction observed in bovine middle cerebral artery. Tohoku J Exp Med 2003; 201(4): 239-249.
62. Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep 2003; 5(2): 155-164.
63. Wingard CJ, Husain S, Williams J, James S. RhoA-Rho kinase mediates synergistic ET-1 and phenylephrine contraction of rat corpus cavernosum. Am J Physiol Regul Integr Comp Physiol 2003; 285(5): R1145-R1152.
64. Akiyama N, Naruse K, Kobayashi Y, et al. High glucose-induced upregulation of Rho/Rho-kinase via platelet-derived growth factor receptor-β increases migration of aortic smooth muscle cells. J Mol Cell Cardiol 2008; 45(2): 326-332.
65. Rajagopalan LE, Davies MS, Kahn LE, et al. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity. J Pharmacol Exp Ther 2010; 333(3): 707-716.
66. Rikitake Y, Liao JK. Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 2005; 111(24): 3261-3268.
67. Iwasaki H, Okamoto R, Kato S, et al. High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-κB activation in bovine aortic endothelial cells. Atherosclerosis 2008; 196(1): 22-28.
68. Didion SP, Lynch CM, Baumbach GL, Faraci FM. Impaired endothelium-dependent responses and enhanced influence of rho-kinase in cerebral arterioles in type II diabetes. Stroke 2005; 36(2): 342-347.
69. Didion SP, Lynch CM, Faraci FM. Cerebral vascular dysfunction in TallyHo mice: a new model of type II diabetes. Am J Physiol Heart Circ Physiol 2007; 292(3): H1579-H1583.
70. Naik JS, Xiang L, Hester RL. Enhanced role for RhoA-associated kinase in adrenergic-mediated vasoconstriction in gracilis arteries from obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2006; 290(1): R154-R161.
71. Failli P, Alfarano C, Franchi-Micheli S, et al. Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. Cardiovasc Diabetol 2009; 8: 32.
72. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112(8): 417-428.
73. Romero MJ, Platt DH, Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008; 102(1): 95-102.
74. Nakamura T, Fukui M, Ebihara I, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993; 42(3): 450-456.
75. Zyadeh FN, Sharma K, Erickson M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose in mediated by autocrine activation of transforming growth factor-β. J Clin Invest 1994; 93(2): 536-542.
76. Gojo A, Utsunomiya K, Taniguchi K, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol 2007; 568(1-3): 242-247.
77. Fornoni A, Ijaz A, Tejada T, Lenz O. Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 2008; 4(1): 10-17.
78. Kolavennu V, Zeng LX, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57(3): 714-723.
79. Peng FF, Wu DC, Gao B, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57(6): 1683-1692.
80. Kikuchi Y, Yamada M, Imakiire T, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192(3): 595-603.
81. Komers R, Oyama TT, Beard DR, et al. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int 2011; 79(4): 432-442.
82. Usui HK, Shikata K, Sasaki M, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007; 56(2): 363-372.
83. Wang FR, Li M, Cheng L, et al. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci 2008; 83(25-26): 828-835.
84. Kikuchi Y, Imakiire T, Yamada M, et al. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 2005; 20(8): 1573-1581.
85. Satoh S, Yamaguchi T, Hitomi A, et al. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 2002; 455(2-3): 169-174.
86. Komers R, Oyama TT, Beard DR, Anderson S. Effects of systemic inhibition of Rho kinase on blood pressure and renal haemodynamics in diabetic rats. Br J Pharmacol 2011; 162(1): 163-174.
87. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146(5): 1029-1039.
88. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92(3): 905-909.
89. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003; 52(3): 838-845.
90. Yokota T, Utsunomiya K, Taniguchi K, Gojo A, Kurata H, Tajima N. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol 2007; 51(6): 424-430.
91. Gordon B, Chang S, Kavanagh M, et al. The effect of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112(4): 385-391.
92. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56(1): 1-11.
93. Cusick M, Chew EY, Chan CC, Kruth HS, Murphy RP, Ferris FL III. Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. Ophthalmology 2003; 110(11): 2126-2133.
94. Kern TS, Miller CM, Du Y, et al. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007; 56(2): 373-379.
95. Yang LP, Sun HL, Wu LM, et al. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009; 50(5): 2319-2327.
96. Arita R, Hata Y, Nakao S, et al. Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes 2009; 58(1): 215-226.
97. Kita T, Hata Y, Arita R, et al. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci USA 2008; 105(45): 17504-17509.
98. Kawahara S, Hata Y, Kita T, et al. Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statin. Diabetes 2008; 57(10): 2784-2793.
99. Vickers MA, Wright EA. Erectile dysfunction in the patient with diabetes mellitus. Am J Manag Care 2004; 10(1 Suppl.): S3-S11.
100. Bivalacqua TJ, Champion HC, Usta MF, et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004; 101(24): 9121-9126.
101. Murat N, Soner BC, Demir O, Esen A, Gidener S. Contractility of diabetic human corpus cavernosum smooth muscle in response to serotonin mediated via Rho-kinase. Pharmacology 2009; 84(1): 24-28.
102. Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med 2007; 4(3): 620-630.
103. Wang H, Eto M, Steers WD, Somlyo AP, Somlyo AV. RhoA-mediated Ca2+ sensitization in erectile function. J Biol Chem 2002; 277(34): 30614-30621.
104. Chang S, Hypolite JA, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003; 15(1): 53-62.
105. Chiou WF, Liu HK, Juan CW. Abnormal protein expression in the corpus cavernosum impairs erectile function in type 2 diabetes. BJU Int 2010; 105(5): 674-680.
106. Tiftik RN, Erol A, Cnar MG, et al. Nitric oxide does not downregulate Rho-kinase (ROCK-2) expression in rat coronary endothelial cells. J Cardiovasc Pharmacol 2008; 51(2): 140-147.
107. Wingard C, Fulton D, Husain S. Altered penile vascular reactivity and erection in the Zucker obese-diabetic rat. J Sex Med 2007; 4(2): 348-362.
108. Wingard CJ, Moukdar F, Prasad RY, Cathey BL, Wilkinson L. Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling. J Sex Med 2009; 6(Suppl. l3): 269-278.
109. Poladia DP, Bauer JA. Functional, structural, and neuronal alterations in urinary bladder during diabetes: investigations of a mouse model. Pharmacology 2005; 74(2): 84-94.
110. Takahashi R, Nishimura J, Hirano K, Seki N, Naito S, Kanaide H. Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol 2004; 172(2): 748-752.
111. Wang T, Kendig DM, Smolock EM, Moreland RS. Carbachol-induced rabbit bladder smooth muscle contraction: roles of protein kinase C and Rho kinase. Am J Physiol Renal Physiol 2009; 297(6): F1534-F1542.
112. Chang S, Hypolite JA, DiSanto ME, Changolkar A, Wein AJ, Chacko S. Increased basal phosphorylation of detrusor smooth muscle myosin in alloxan-induced diabetic rabbit is mediated by upregulation of Rho-kinase beta and CPI-17. Am J Physiol Renal Physiol 2006; 290(3): F650-F656.
113. Nobe K, Yamazaki T, Kumai T, et al. Alterations of glucose-dependent and independent bladder smooth muscle contraction in spontaneously hypertensive and hyperlipidemic rat. J Pharmacol Exp Ther 2008; 324(2): 631-642.
114. Nobe K, Yamazaki T, Tsumita N, Hashimoto T, Honda K. Glucose-dependent enhancement of diabetic bladder contraction is associated with a rho kinase-regulated protein kinase C pathway. J Pharmacol Exp Ther 2009; 328(3): 940-950.
115. Ismael HN, Mustafa S, Thulesius O. Effect of diabetes on cooling-induced detrusor muscle contraction: mediation via Rho-kinase activation. Urology 2010; 75(4): 891-895.
116. Lin G, Craig GP, Zhang L, et al. Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc Res 2007; 75(1): 51-58.
117. Tang J, Fitzgerald SM, Boughtman BN, Cole SW, Brands MW, Zhang JH. Decreased RhoA expression in myocardium of diabetic rats. Can J Physiol Pharmacol 2005; 83(8-9): 775-783.
118. Soliman H, Craig GP, Nagareddy P, et al. Role of inducible nitric oxide synthase in induction of RhoA expression in hearts from diabetic rats. Cardiovasc Res 2008; 79(2): 322-330.
119. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med 2007; 262(2): 173-183.
120. Hartge MM, Unger T, Kintscher U. The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007; 4(2): 84-88.
121. Gunnett CA, Lund DD, McDowell AK, Faraci FM, Heistad DD. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler Thromb Vasc Biol 2005; 25(8): 1617-1622.
122. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006; (176 Pt 1): 213-254.
123. Griscavage JM, Hobbs AJ, Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 1995; 34: 215-234.
124. Nagareddy PR, Xia Z, McNeill JH, MacLeod KM. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin-induced diabetes. Am J Physiol Heart Circ Physiol 2005; 289(5): H2144-H2152.
125. Grönholm T, Cheng ZJ, Palojoki E, et al. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats. Eur J Pharmacol 2005; 519(3): 267-276.
126. Ren J, Duan J, Thomas DP, et al. IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol 2008; 294(3): R793-R802.
127. Jensen TS, Backonja MM, Hernández Jiménez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006; 3(2): 108-119.
128. Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain 2006; 22(8): 681-685.
129. Ii M, Nishimura H, Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005; 112(1): 93-102.
130. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract 2003; 61(Suppl. 1)): S35-S39.
131. Fried LF, Forrest KY, Ellis D, Chang Y, Silvers N, Orchard TJ. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15(3): 113-119.
132. Ohsawa M, Aasato M, Hayashi SS, Kamei J. RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice. Pain 2011; 152(1): 114-122.
133. Bach LA. Rho kinase inhibition: a new approach for treating diabetic nephropathy? Diabetes 2008; 57(3): 532-533.
134. Arita R, Hata Y, Ishibashi T. ROCK as a therapeutic target of diabetic retinopathy. J Ophthalmol 2010; 2010: 175163.
135. Tonelli M, Keech A, Sheherd J, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005; 16(12): 3748-3754.
136. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22(1): 118-127.
137. Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008; 19(7): 709-718.